» Articles » PMID: 17106215

Impact of FDG-PET/MRI Image Fusion on the Detection of Pancreatic Cancer

Overview
Journal Pancreatology
Date 2006 Nov 16
PMID 17106215
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: This study assessed the value of image fusion with (18)F-fluorodeoxyglucose-positron emission tomography (FDG-PET) and magnetic resonance imaging (MRI) in patients suspected of having pancreatic cancer.

Methods: 32 patients (12 women, 20 men; age 24-79 years; mean 56.6 years) were included. All patients underwent whole-body FDG-PET examinations and contrast-enhanced MRI. Image fusion used a semiautomatic voxel-based algorithm. Separate reading, side-by-side analysis and evaluation of fused PET/MRI images were performed. Results were correlated to histopathology (n = 30), or clinical follow-up (n = 2).

Results: 15/32 patients had pancreas cancer and 17/32 patients benign disease. The sensitivity and specificity for cancer detection by FDG-PET were 93 and 41% for visual and 86 and 58% for semiquantitative analysis whereas MRI achieved 100 and 76% respectively. Topographical assignment of PET foci by image fusion was superior to side-by-side analysis in 11/39 (28%) foci (in 8/32 patients). However, a true impact on therapeutic strategy was observed only in 1/8 patients as the presence of multiple metastases, irresectable primaries or medical reasons for inoperability prevented a curative setting.

Conclusion: Compared to side-by-side analysis, PET/MRI image fusion improves the anatomical assignment and interpretation of FDG foci. The therapeutic benefit for the patient however is limited in patients with multiple lesions or incurable primaries.

Citing Articles

Beyond chimerism analysis: methods for tracking a new generation of cell-based medicines.

Vives J, Casademont-Roca A, Martorell L, Nogues N Bone Marrow Transplant. 2020; 55(7):1229-1239.

PMID: 32024991 DOI: 10.1038/s41409-020-0822-8.


White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, update on imaging techniques and screening of pancreatic cancer in high-risk individuals.

Kulkarni N, Mannelli L, Zins M, Bhosale P, Arif-Tiwari H, Brook O Abdom Radiol (NY). 2019; 45(3):729-742.

PMID: 31768594 DOI: 10.1007/s00261-019-02290-y.


DNA-SWCNT Biosensors Allow Real-Time Monitoring of Therapeutic Responses in Pancreatic Ductal Adenocarcinoma.

Bhattacharya S, Gong X, Wang E, Dutta S, Caplette J, Son M Cancer Res. 2019; 79(17):4515-4523.

PMID: 31292162 PMC: 6726513. DOI: 10.1158/0008-5472.CAN-18-3337.


Current Status and Future Directions for Screening Patients at High Risk for Pancreatic Cancer.

McAllister F, Montiel M, Uberoi G, Uberoi A, Maitra A, Bhutani M Gastroenterol Hepatol (N Y). 2017; 13(5):268-275.

PMID: 28656024 PMC: 5479340.


Imaging modalities for characterising focal pancreatic lesions.

Best L, Rawji V, Pereira S, Davidson B, Gurusamy K Cochrane Database Syst Rev. 2017; 4:CD010213.

PMID: 28415140 PMC: 6478242. DOI: 10.1002/14651858.CD010213.pub2.